Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")
about
Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsMechanisms of drug resistance: daptomycin resistanceWhat's new in multidrug-resistant pathogens in the ICU?Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelCeftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates.Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibioticsAmpicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.Evolving resistance among Gram-positive pathogensStepwise decrease in daptomycin susceptibility in clinical Staphylococcus aureus isolates associated with an initial mutation in rpoB and a compensatory inactivation of the clpX gene.Differential Adaptations of Methicillin-Resistant Staphylococcus aureus to Serial In Vitro Passage in Daptomycin: Evolution of Daptomycin Resistance and Role of Membrane Carotenoid Content and Fluidity.Poorly Cross-Linked Peptidoglycan in MRSA Due to mecA Induction Activates the Inflammasome and Exacerbates ImmunopathologyTelavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin SynergyUse of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin bindingDaptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in Staphylococcus aureusStudies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant.A current perspective on daptomycin for the clinical microbiologist.Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistanceMolecular Bases Determining Daptomycin Resistance-Mediated Resensitization to β-Lactams (Seesaw Effect) in Methicillin-Resistant Staphylococcus aureus.β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone.Inhibitors targeting on cell wall biosynthesis pathway of MRSA.Current and prospective treatments for multidrug-resistant gram-positive infections.Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus.Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections.Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013.Daptomycin-β-Lactam Combinations in a Rabbit Model of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Endocarditis.Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin.
P2860
Q26752922-EAA19DD5-3A14-429F-B319-D9EA3A8EE2ACQ26779944-F5BEF519-7B1D-46B2-B2C2-7B0FB9A52EA9Q28071346-CD76B874-E507-43FB-9908-ECE44FAA5CB2Q28481497-0500D7EE-7B96-4AF1-953B-24E68C55187DQ30452801-4030A978-77FA-4FE4-87C8-4466CAD7BEC8Q31131146-15E9D083-22C7-48C9-BDD6-CC27E51C1D29Q34157657-AAA5771C-4B64-4DBB-81CE-77D508115655Q34478074-305B9A1B-DC3F-46A0-AFD7-C6F9606FD234Q34648042-64F88FB3-DFE6-4751-845C-EB3536F6F25CQ35179800-65F49A03-40C1-4D0A-95B4-30D59DE21BEBQ35191555-4637D4B8-FDAB-4D11-8DF9-4D89BE064131Q35385568-42577135-8E06-4F92-8C5F-0C1C1A01213DQ35689222-F7480F21-70B3-438A-8B49-09B57DB93D7AQ35999912-7D7604ED-99D1-4B26-85EB-E84408E105A6Q36158472-235206C4-F035-47F0-94E1-8EC08CD88A47Q36200018-EBD4BA0A-07F1-48D4-A903-9117868788DDQ36289191-AE70FDD6-51A2-4ED8-B461-A4ECE5387D0CQ36364106-BB7BB2D3-C943-46C4-B283-8F3164629DBFQ36396117-3BDE58BA-6404-4786-8175-2037245D46E2Q36439093-0F44520C-E4C1-4188-AD58-C420D7895277Q36970335-5A11F0A6-EFDD-4935-AC6C-7D70C7A3ECC0Q37023118-210B7471-9D83-4C4F-A3F4-2078E5F9A45BQ37036548-F9418D58-4603-46C0-9BA5-76C6F374ADE3Q37190222-CF276B48-992F-4F32-8367-62F96576F209Q37263289-8CA24577-CB5C-421E-8117-9C03E3815D2BQ37263514-B627025F-8C84-4F36-B0C5-64E173F64C14Q37538754-63EEBA17-74BE-4222-A57A-41C5BA61434CQ37544579-01740066-AC14-4A7A-B869-7E1213573E12Q38035171-88DC3181-80B0-4F3B-8D98-EBBDD2CB14BFQ38123255-CA03D733-7696-4CE6-A4A9-57CB12C2CD02Q38627239-95F54849-1F2E-4974-97F5-7C2CB502902DQ38926289-CE293074-FC06-470A-9D77-AD12492B0C32Q39016281-B1472693-05C3-4D99-80FC-9006E9171879Q40320011-B5E27C48-233B-4B7A-B1C3-B4DC601AEEECQ40327375-C655E809-93C5-4C1E-8F6F-16484DB1BA9CQ40360449-44C14F23-83FF-49E6-B7B9-BD7A1EF2E10CQ40631566-C8F9F4ED-B51B-4AC5-B7E8-65506CB5A5F7Q40706134-53721562-354D-49A0-A0FF-03FCDBD5C8F3Q40709730-C69D14C9-083C-4D82-82D2-BFDE5082E59DQ40758601-59C1C0A5-3264-43F0-B612-6F6C15D72BFC
P2860
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect")
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Daptomycin-oxacillin combinati ...... tibility (the "seesaw effect")
@ast
Daptomycin-oxacillin combinati ...... tibility (the "seesaw effect")
@en
Daptomycin-oxacillin combinati ...... lving oxacillin susceptibility
@nl
type
label
Daptomycin-oxacillin combinati ...... tibility (the "seesaw effect")
@ast
Daptomycin-oxacillin combinati ...... tibility (the "seesaw effect")
@en
Daptomycin-oxacillin combinati ...... lving oxacillin susceptibility
@nl
prefLabel
Daptomycin-oxacillin combinati ...... tibility (the "seesaw effect")
@ast
Daptomycin-oxacillin combinati ...... tibility (the "seesaw effect")
@en
Daptomycin-oxacillin combinati ...... lving oxacillin susceptibility
@nl
P2093
P2860
P356
P1476
Daptomycin-oxacillin combinati ...... tibility (the "seesaw effect")
@en
P2093
Arnold S Bayer
Robert Daum
Soo-Jin Yang
Susan Boyle-Vavra
Tiffanny Jones
Yan Q Xiong
P2860
P304
P356
10.1128/AAC.00487-10
P407
P577
2010-06-14T00:00:00Z